NasdaqGS:SGEN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. More Details


Snowflake Analysis

Flawless balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Seagen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SGEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: SGEN's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

4.6%

SGEN

3.5%

US Biotechs

-1.0%

US Market


1 Year Return

70.4%

SGEN

36.8%

US Biotechs

19.6%

US Market

Return vs Industry: SGEN exceeded the US Biotechs industry which returned 36.8% over the past year.

Return vs Market: SGEN exceeded the US Market which returned 19.6% over the past year.


Shareholder returns

SGENIndustryMarket
7 Day4.6%3.5%-1.0%
30 Day-6.1%4.5%2.2%
90 Day-7.6%19.2%11.5%
1 Year70.4%70.4%39.0%36.8%22.3%19.6%
3 Year247.3%247.3%30.5%23.6%45.3%35.7%
5 Year393.9%393.9%43.9%33.0%124.8%99.8%

Long-Term Price Volatility Vs. Market

How volatile is Seagen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Seagen undervalued compared to its fair value and its price relative to the market?

45.6%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SGEN ($185.75) is trading below our estimate of fair value ($341.31)

Significantly Below Fair Value: SGEN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SGEN is poor value based on its PE Ratio (68x) compared to the US Biotechs industry average (33.1x).

PE vs Market: SGEN is poor value based on its PE Ratio (68x) compared to the US market (21x).


Price to Earnings Growth Ratio

PEG Ratio: SGEN is poor value based on its PEG Ratio (1.6x)


Price to Book Ratio

PB vs Industry: SGEN is overvalued based on its PB Ratio (14.4x) compared to the US Biotechs industry average (4.2x).


Next Steps

Future Growth

How is Seagen forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?

41.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SGEN's forecast earnings growth (41.6% per year) is above the savings rate (2%).

Earnings vs Market: SGEN's earnings (41.6% per year) are forecast to grow faster than the US market (21.6% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SGEN's revenue (25% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: SGEN's revenue (25% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SGEN's Return on Equity is forecast to be low in 3 years time (14.2%).


Next Steps

Past Performance

How has Seagen performed over the past 5 years?

3.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SGEN has high quality earnings.

Growing Profit Margin: SGEN became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: SGEN has become profitable over the past 5 years, growing earnings by 3.1% per year.

Accelerating Growth: SGEN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: SGEN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: SGEN's Return on Equity (20.9%) is considered high.


Next Steps

Financial Health

How is Seagen's financial position?


Financial Position Analysis

Short Term Liabilities: SGEN's short term assets ($2.2B) exceed its short term liabilities ($593.1M).

Long Term Liabilities: SGEN's short term assets ($2.2B) exceed its long term liabilities ($153.8M).


Debt to Equity History and Analysis

Debt Level: SGEN is debt free.

Reducing Debt: SGEN has not had any debt for past 5 years.

Debt Coverage: SGEN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: SGEN has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Seagen current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SGEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.7yrs

Average management tenure


CEO

Clay Siegall (59 yo)

18.17yrs

Tenure

US$14,521,495

Compensation

Dr. Clay B. Siegall, Ph.D. co-founded Seagen Inc. (formerly known as Seattle Genetics, Inc.). in 1997 and has been its Chief Executive Officer since November 2002 and its President since June 2000. Dr. Sie...


CEO Compensation Analysis

Compensation vs Market: Clay's total compensation ($USD14.52M) is above average for companies of similar size in the US market ($USD10.56M).

Compensation vs Earnings: Clay's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Clay Siegall
Co-Founder18.17yrsUS$14.52m0.33%
$ 110.6m
Todd Simpson
Chief Financial Officer15.25yrsUS$4.49m0.046%
$ 15.3m
Jean Liu
General Counsel6.17yrsUS$3.97m0.016%
$ 5.3m
Roger Dansey
Chief Medical Officer2.67yrsUS$6.72m0.019%
$ 6.4m
Vaughn Himes
Chief Technical Officer4.42yrsUS$3.95m0.084%
$ 28.2m
Peggy Pinkston
VP of Investor Relationsno datano datano data
Nancy Whiting
Executive VP of Corporate Strategyno datano datano data
Natasha Hernday
Executive Vice President of Corporate Development9.75yrsno datano data
Matt Skelton
Vice President of Marketing5.17yrsno datano data
Christopher Pawlowicz
Executive Vice President of Human Resourcesno datano datano data
Charles Romp
Executive Vice President of Commercial U.S.no datano data0.024%
$ 8.2m
Dennis Benjamin
Senior Vice President of Translational Research4.25yrsno datano data

5.7yrs

Average Tenure

59yo

Average Age

Experienced Management: SGEN's management team is seasoned and experienced (5.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Clay Siegall
Co-Founder18.17yrsUS$14.52m0.33%
$ 110.6m
John Orwin
Independent Director7yrsUS$442.77k0.012%
$ 4.0m
David Gryska
Independent Director15.83yrsUS$445.63k0.024%
$ 8.1m
Daniel Welch
Independent Director13.58yrsUS$431.04k0.025%
$ 8.5m
Felix Baker
Lead Independent Director15.92yrsUS$482.74k0.11%
$ 37.1m
Ted Love
Director0.42yrno data0.00099%
$ 332.7k
Marc Lippman
Independent Director20.58yrsUS$427.60k0.028%
$ 9.5m
Nancy Simonian
Independent Director8.83yrsUS$435.63k0.012%
$ 4.0m
Alpna Seth
Independent Director2.83yrsUS$433.04k0%
$ 0

13.6yrs

Average Tenure

59yo

Average Age

Experienced Board: SGEN's board of directors are seasoned and experienced ( 13.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SGEN insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.5%.


Top Shareholders

Company Information

Seagen Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Seagen Inc.
  • Ticker: SGEN
  • Exchange: NasdaqGS
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$33.601b
  • Shares outstanding: 180.90m
  • Website: https://www.seagen.com

Number of Employees


Location

  • Seagen Inc.
  • Building 3
  • 21717 30th Drive S.E
  • Bothell
  • Washington
  • 98021
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SGENNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDMar 2001
SGTDB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2001
SGEN *BMV (Bolsa Mexicana de Valores)YesCommon SharesMXMXNMar 2001
S1GE34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 20 REPR 1 COM NPVBRBRLOct 2020

Biography

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (A...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/16 23:04
End of Day Share Price2021/01/15 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.